Results 111 to 120 of about 114,065 (338)

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Quality of life of caregivers and impact on the nuclear family of children with leukaemia in the National Cancer Institute of Sri Lanka [PDF]

, 2015
Childhood leukaemia is the commonest cancer in children aged below 15 years. A diagnosis of childhood leukaemia is a devastating experience for any parent. This hospital-based descriptive cross sectional study aimed to assess the quality of life (QOL) of
Goonawardena, C S E, Pathirana, Thanya I., Wijesiriwardane, I   +2 more
core   +1 more source

Dual‐Targeting Cuproptosis and Mitophagy via a Flavopiridol‐Copper Nanoplatform Potentiates Immunotherapy Against Uveal Melanoma

Advanced Science, EarlyView.
This study develops a GSH‐responsive nanoplatform, NP@Fla‐Cu, to co‐activate cuproptosis and excessive mitophagy in uveal melanoma. The nanoplatform enhances tumor‐specific copper delivery, depletes antioxidant defenses, and remodels the tumor immune microenvironment.
Hong Ren, Zhihong Deng, Sheng Lu, Jing Zhang, Wenbin Liu, Jia Tan   +5 more
wiley   +1 more source

Cost-effectiveness analysis in R using a multi-state modelling survival analysis framework: a tutorial [PDF]

, 2016
This tutorial provides a step-by-step guide to performing cost-effectiveness analysis using a multi-state modelling approach. Alongside the tutorial we provide easy-to-use functions in the statistics package R.
Briggs, Andrew H., Lewsey, James D., Mackay, Daniel F., Williams, Claire   +3 more
core   +2 more sources

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, EarlyView.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia

Nature Communications, 2017
ATM and TP53 mutations are associated with poor prognosis in chronic lymphocytic leukaemia (CLL). Here the authors generate mouse models of Tp53- and Atm-defective CLL mimicking the high-risk form of human disease and show that Atm-deficient CLL is ...
Gero Knittel, Tim Rehkämper, Darya Korovkina, Paul Liedgens, Christian Fritz, Alessandro Torgovnick, Yussor Al-Baldawi, Mona Al-Maarri, Yupeng Cun, Oleg Fedorchenko, Arina Riabinska, Filippo Beleggia, Phuong-Hien Nguyen, F. Thomas Wunderlich, Monika Ortmann, Manuel Montesinos-Rongen, Eugen Tausch, Stephan Stilgenbauer, Lukas P. Frenzel, Marco Herling, Carmen Herling, Jasmin Bahlo, Michael Hallek, Martin Peifer, Reinhard Buettner, Thorsten Persigehl, H. Christian Reinhardt   +26 more
doaj   +1 more source

Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational study

Mycoses (Berlin), 2019
Invasive fungal diseases (IFD) are life‐threatening infections most commonly diagnosed in acute leukaemia patients with prolonged neutropenia and are uncommonly diagnosed in patients with lymphoproliferative diseases.
R. Ruchlemer, R. Ben-Ami, M. Bar-Meir, Jennifer R. Brown, M. Malphettes, R. Mous, S. Tonino, C. Soussain, N. Barzic, J. Messina, P. Jain, R. Cohen, B. Hill, S. Mulligan, M. Nijland, Y. Herishanu, O. Benjamini, T. Tadmor, K. Okamoto, B. Arthurs, B. Gottesman, A. Kater, M. Talha, B. Eichhorst, M. Korem, N. Bogot, F. de Boer, J. Rowe, T. Lachish   +28 more
semanticscholar   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Nature Communications, 2019
The BCL-2 mutation G101V reduces venetoclax affinity and confers drug resistance in patients with chronic lymphocytic leukaemia. Here, the authors present crystal structures and biochemical analyses of venetoclax bound to BCL-2 and the G101V mutant ...
Richard W. Birkinshaw, Jia-nan Gong, Cindy S. Luo, Daisy Lio, Christine A. White, Mary Ann Anderson, Piers Blombery, Guillaume Lessene, Ian J. Majewski, Rachel Thijssen, Andrew W. Roberts, David C. S. Huang, Peter M. Colman, Peter E. Czabotar   +13 more
doaj   +1 more source

Chronic lymphocytic leukaemia with concomitant plasmablastic lymphoma

South African Journal of Oncology, 2017
Plasmablastic lymphomas are high-grade lymphomas that usually occur in immune-suppressed patients. Occasionally, they can arise from an underlying haematolymphoid malignancy, termed ‘transformed plasmablastic lymphoma’. In this report, we describe a case
Jacqueline Goedhals, Leriska Haupt, Deborah Jafta   +2 more
doaj   +1 more source